Association between primary tumor site of colorectal cancer and RAS/BRAF mutational status with venous thromboembolism: A retrospective-prospective cohort study from 3 Croatian oncology centers

被引：0

作者：

Zlatovic, J. Jovic ^{[1
]}

Bevanda, M. ^{[2
]}

Skelin, M. ^{[3
]}

Dobric, V. Telesmanic ^{[4
]}

Curic, Z. ^{[5
]}

Marijanovic, I. ^{[6
]}

Grubisic-Cabo, F. ^{[1
]}

Krecak, I. ^{[1
]}

Tomic, S. ^{[7
]}

Kralik, K. ^{[8
]}

Omrcen, T. ^{[9
]}

机构：

[1] Gen Hosp Sibenik Knin Cty, Dept Internal Med, Shibenik, Croatia

[2] Univ Hosp Mostar, Dept Gastroenterol, Mostar, Bosnia & Herceg

[3] Gen Hosp Sibenik Knin Cty, Dept Pharm, Shibenik, Croatia

[4] Gen Hosp Zadar, Dept Oncol & Nucl Med, Zadar, Croatia

[5] Gen Hosp Dubrovnik, Dept Oncol, Dubrovnik, Croatia

[6] Univ Clin Hosp Mostar, Oncol Clin, Mostar, Bosnia & Herceg

[7] Univ Hosp Ctr Split, Dept Pathol Citol & Forens Med, Split, Croatia

[8] Univ Osijek, Fac Med Osijek, Osijek, Croatia

[9] Univ Hosp Split, Dept Oncol & Radiotherapy, Split, Croatia

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.04.296

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-206

引用

页码：S322 / S323

页数：2

共 6 条

[1] Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer
Christensen, Troels Dreier
Palshof, Jesper Andreas
Larsen, Finn Ole
Poulsen, Tim Svenstrup
Hogdall, Estrid
Pfeiffer, Per
Jensen, Benny Vittrup
Yilmaz, Mette Karen
Nielsen, Dorte
ACTA ONCOLOGICA, 2018, 57 (08) : 1057 - 1062
[2] Association between level of tumor markers and development of venous thromboembolism in patients with pancreatic, colorectal and ovarian cancer: A retrospective case-control study.
Rai, Srijana
Awkar, Nelly
Katpally, Ram
Shaaban, Hamid Salim
McGarry, Megan
Tibayan, Resty
Guron, Gunwant K.
Maroules, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[3] Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial
Noepel-Duennebacke, Stefanie
Arnold, Dirk
Hertel, Jan
Tannapfel, Andrea
Hinke, Axel
Hegewisch-Becker, Susanna
Reinacher-Schick, Anke
CLINICAL COLORECTAL CANCER, 2018, 17 (04) : E733 - E739
[4] Heterogeneity of KRAS, NRAS, PIK3CA and BRAF mutational status in primary tumor, lymph nodes and liver metastases obtained from patients with metastatic colorectal cancer
del Carmen, S.
Sayagues, J.
Bengoechea, O.
Alcazar, J.
Gervas, R.
Garcia, J.
Orfao, A.
Sarasquete, M.
Abad, M.
EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 396 - 397
[5] Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan
Taniguchi, Hiroya
Uehara, Keisuke
Nakayama, Goro
Nakayama, Hiroshi
Aiba, Toshisada
Hattori, Norifumi
Kataoka, Masato
Nakano, Yasuyuki
Kawase, Yoshihisa
Okochi, Osamu
Matsuoka, Hiroshi
Utsunomiya, Setsuo
Sakamoto, Eiji
Mori, Yoshinori
Umeda, Shinichi
Shikano, Toshio
Komori, Koji
Tajika, Masahiro
Kadowaki, Shigenori
Muro, Kei
Yatabe, Yasushi
TRANSLATIONAL ONCOLOGY, 2020, 13 (07):
[6] Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
Valladares-Ayerbes, M.
Safont, M. J.
Gonzalez-Flores, E.
Garcia-Alfonso, P.
E. Aranda Aguilar
A. M. Lopez Munoz
L. Cirera Nogueras
Ferrer, E. Falco
N. Rodriguez Salas
Aparicio, J.
Llanos, M.
O. A. Castillo Trujillo
P. Pimentel Caceres
Cruz-Hernandez, J. J.
M. Salgado Fernandez
A. Salud Salvia
Garcia-Carbonero, R.
B. Massuti Sureda
M. A. Vicente Conesa
A. Lloansi Vila
ANNALS OF ONCOLOGY, 2021, 32 : S560 - S560

← 1 →